Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation

Thrombocytopenia occurs commonly after hematopoietic progenitor cell transplantation (HPCT) and is associated with potential morbidity and mortality. Few studies have examined the impact of platelet (PLT) transfusion on clinical outcomes in HPCT while optimal PLT transfusion strategies after HSCT remain uncertain.

[1]  E. Wood,et al.  A no-prophylaxis platelet-transfusion strategy for hematologic cancers. , 2013, The New England journal of medicine.

[2]  A. Ho,et al.  Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study , 2012, The Lancet.

[3]  S. Hopewell,et al.  Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. , 2012, The Cochrane database of systematic reviews.

[4]  D. Allan,et al.  Storage time of transfused red blood cells and impact on clinical outcomes in hematopoietic stem cell transplantation , 2011, Transfusion.

[5]  E. Vamvakas.  COMMENTARY: Relative safety of pooled whole blood–derived versus single‐donor (apheresis) platelets in the United States: a systematic review of disparate risks , 2009, Transfusion.

[6]  T. Hervig,et al.  A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. , 2009, Blood.

[7]  Neil Blumberg,et al.  The platelet as an immune cell—CD40 ligand and transfusion immunomodulation , 2009, Immunologic research.

[8]  D. Allan,et al.  Reduced hemoglobin on day of peripheral blood progenitor cell collection is associated with low graft content of vascular progenitors and increased toxicity after autologous hematopoietic stem cell transplantation , 2008, Transfusion.

[9]  N. Heddle,et al.  Comparing the efficacy and safety of apheresis and whole blood–derived platelet transfusions: a systematic review , 2008, Transfusion.

[10]  C. Ramos,et al.  Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation , 2007, Bone Marrow Transplantation.

[11]  Edward J. Lee,et al.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. , 2005, Blood.

[12]  F. Frassoni,et al.  Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft‐versus‐host disease, donor type, cytomegalovirus infections and cell dose , 2001, British journal of haematology.

[13]  J. Vose,et al.  A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. , 1998, Blood.

[14]  F. Appelbaum,et al.  Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Moore,et al.  Diagnostic and pathogenetic considerations in transfusion‐related acute lung injury , 1985, Transfusion.